# US 2021/0260118 A1 · Bcma car-t cells with enhanced activities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260118 A1
- Document ID: US20210260118A1
- Status: Published application
- Kind: A1
- Application number: 17/183,689
- Filed: 2021-02-24
- Published: 2021-08-26
- Earliest claimed: 2020-02-24
- Assignees: Allogene Therapeutics, Inc.
- Applicants: Allogene Therapeutics, Inc.
- Inventors: Regina Junhui LIN; Siler PANOWSKI; Cesar Adolfo SOMMER; Thomas John VAN BLARCOM; Barbra Johnson SASU; Arun BALAKUMARAN
- Web page: https://patentgrep.com/patent/US20210260118A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 5/0636: {T lymphocytes}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.

## Claims

### Claim 1

An engineered immune cell comprising an anti-BCMA chimeric antigen receptor (CAR) and a constitutively active chimeric cytokine receptor (CACCR), wherein the CACCR comprises two monomers, each monomer comprising:
a transmembrane domain;
a Janus Kinase (JAK)-binding domain; and
a recruiting domain,
wherein the CACCR does not comprise an extracellular ligand-binding domain.

### Claim 2 (depends on 1)

The engineered immune cell of claim 1 wherein the transmembrane domain and JAK-binding domain are present in a polypeptide (“TM/JAK polypeptide”) that comprises an amino acid sequence that is at least about 90% identical to amino acids 478-582 of the naturally occurring TPOR/MPLR receptor (SEQ ID NO: 7).

### Claim 3 (depends on 2)

The engineered immune cell of claim 2 wherein the TM/JAK polypeptide comprises a modified version of the sequence of amino acids 478-582 of the naturally occurring TPOR/MPLR receptor wherein the modified version comprises at least one amino acid substitution at the amino acid position selected from H499, S505, and W515.

### Claim 4 (depends on 3)

The engineered immune cell of claim 3 wherein the modified version of the sequence of amino acids 478-582 of the naturally occurring TPOR/MPLR receptor comprises at least one amino acid substitution selected from the group consisting of H499L, S505N, and W515K.

### Claim 5 (depends on 1)

The engineered immune cell of claim 1, wherein the recruiting domain comprises an amino acid sequence that is at least about 90% identical to the STAT-recruiting domain from IL7Ra, IL2Rb, IL12Rb1, IL12Rb2, or IL21R.

### Claim 6 (depends on 1)

The engineered immune cell of claim 1, wherein the recruiting domain comprises an amino acid sequence that is at least about 90% identical to the STAT-recruiting domain from IL2Rb.

### Claim 7 (depends on 1)

The engineered immune cell of claim 1, wherein the recruiting domain comprises an amino acid sequence that is at least about 90% identical to an amino acid sequence that comprises amino acids 339-379, 393-433, and 518-551 of IL2Rb (SEQ ID NO: 78) or an amino acid sequence that is at least about 90% identical to an amino acid sequence that comprises amino acids 393-433 and 518-551 of IL2Rb (SEQ ID NO: 77).

### Claim 8 (depends on 7)

The engineered immune cell of claim 7, wherein the recruiting domain comprises amino acids 339-379, 393-433, and 518-551 of IL2Rb (SEQ ID NO: 78) or amino acids 393-433 and 518-551 of IL2Rb (SEQ ID NO: 77).

### Claim 9 (depends on 4)

The engineered immune cell of claim 4, wherein the TM/JAK polypeptide comprises the amino acid substitutions S505N and W515K (SEQ ID NO: 13) and further wherein the recruiting domain comprises amino acids 393-433 and 518-551 of IL2Rb (SEQ ID NO: 77).

### Claim 10 (depends on 4)

The engineered immune cell of claim 4, wherein the TM/JAK polypeptide comprises the amino acid substitutions H499L, S505N, and W515K (SEQ ID NO: 12) and further wherein the recruiting domain comprises amino acids 339-379, 393-433 and 518-551 of IL2Rb (SEQ ID NO: 78).

### Claim 11 (depends on 4)

The engineered immune cell of claim 4, wherein the TM/JAK polypeptide comprises the amino acid substitutions H499L, S505N, and W515K and further wherein the recruiting domain comprises amino acids 393-433 and 518-551 of IL2Rb (SEQ ID NO: 77).

### Claim 12 (depends on 1)

The engineered immune cell of claim 1, wherein the CACCR comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 99, 100, 143, 180, 181, 182, 184, 185 or 186.

### Claim 13 (depends on 1)

The engineered immune cell of claim 1, wherein the CACCR comprises the amino acid sequence of SEQ ID NO: 99, 100, 143, 180, 181, 182, 184, 185 or 186.

### Claim 14 (depends on 1)

The engineered immune cell of claim 1, wherein the BCMA CAR comprises an extracellular ligand-binding domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 15 (depends on 14)

The engineered immune cell of claim 14, wherein the extracellular ligand-binding domain specifically recognizes and binds to human BCMA.

### Claim 16 (depends on 15)

The engineered immune cell of claim 15, wherein the extracellular ligand-binding domain comprises a single chain variable fragment (scFv).

### Claim 17 (depends on 16)

The engineered immune cell of claim 16, wherein the scFv comprises a heavy chain variable (VH) region and a light chain variable (VL) region joined by a flexible linker.

### Claim 18 (depends on 17)

The engineered immune cell of claim 17, wherein the VH region comprises the amino acid sequence of SEQ ID NO: 144 and the VL region comprises the amino acid sequence of SEQ ID NO: 145, or the VH region comprises the amino acid sequence of SEQ ID NO: 155 and the VL region comprises the amino acid sequence of SEQ ID NO: 156.

### Claim 19 (depends on 17)

The engineered immune cell of claim 17, wherein the VH region comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 146, 147, or 148; a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 149 or 150; and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 151; and the VL region comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 152; a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 153; and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 154.

### Claim 20 (depends on 17)

The engineered immune cell of claim 17, wherein the VH region comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 157, 158 or 159; a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 160 or 161; and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 162; and the VL region comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 163; a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 164; and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 165.

### Claim 21 (depends on 15)

The engineered immune cell of claim 15, wherein the intracellular signaling domain of the BCMA CAR comprises a CD3 (CD3zeta) signaling domain and/or a 4-1BB signaling domain.

### Claim 22 (depends on 15)

The engineered immune cell of claim 15, wherein the BCMA CAR comprises a safety switch comprising the CD20 mimotope.

### Claim 23 (depends on 15)

The engineered immune cell of claim 15, wherein the BCMA CAR comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 140, 141 or 166.

### Claim 24 (depends on 15)

The engineered immune cell of claim 15, wherein the BCMA CAR comprises the amino acid sequence of SEQ ID NO: 140, 141 or 166.

### Claim 25

An engineered immune cell that comprises one or more polynucleotides that encode a BCMA CAR polypeptide that comprises the amino acid sequence of SEQ ID NO: 140, 141 or 166 and a CACCR polypeptide that comprises the amino acid sequence of SEQ ID NO: 99, 100, 180, 181, 182, 184, 185 or 186.

### Claim 26 (depends on 25)

The engineered immune cell of claim 25, wherein a single polynucleotide encodes both the polypeptide that comprises the amino acid sequence of SEQ ID NO: 140, 141 or 166 and the polypeptide that comprises the amino acid sequence of SEQ ID NO: 99, 100, 180, 181, 182, 184, 185 or 186.

### Claim 27 (depends on 1)

An engineered immune cell of claim 1 comprising a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 172 or 176.

### Claim 28 (depends on 25)

The engineered immune cell of claim 25, wherein the one or more polynucleotides comprise a promoter.

### Claim 29 (depends on 28)

The engineered immune cell of claim 28, wherein the promoter comprises an EF-1 alpha promoter.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The engineered immune cell of claim 1, wherein the engineered immune cell is an engineered T cell.

### Claim 32 (depends on 31)

The engineered immune cell of claim 31, wherein the engineered T cell is autologous T cell or allogeneic T cell.

### Claim 33 (depends on 1)

The engineered immune cell of claim 1, further comprising one or more genetic modifications in T cell receptor alpha constant region (TRAC) and/or CD52 gene to reduce or negate the expression of TCR alpha and/or CD52.

### Claim 34 (depends on 1)

A method of treating a patient suffering from a disease or condition, wherein the method comprises administering an effective amount of the engineered immune cell of claim 1 to the patient in need thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the disease or condition is multiple myeloma.

### Claim 36 (depends on 34)

The method of claim 34, wherein the engineered immune cell is allogeneic to the patient.

### Claim 37 (depends on 34)

The method of claim 34, wherein the method comprises administering at least one dose of the engineered immune cell to the patient, and further wherein one dose contains between about 7×10{circumflex over ( )}6 cells and about 480×10{circumflex over ( )}6 cells.

### Claim 38 (depends on 37)

The method of claim 37, wherein the dose ranges from about 20×10{circumflex over ( )}6 cells/dose to about 480×10{circumflex over ( )}6 cells/dose or the at least one dose is about 20×10{circumflex over ( )}6 cells/dose, about 40×10{circumflex over ( )}6 cells/dose, about 80×10{circumflex over ( )}6 cells/dose, about 120×10{circumflex over ( )}6 cells/dose, about 240×10{circumflex over ( )}6 cells/dose, about 320×10{circumflex over ( )}6 cells/dose, about 360×10{circumflex over ( )}6 cells/dose, or about 480×10{circumflex over ( )}6 cells/dose.

### Claim 39

At least one isolated polynucleotide encoding a BCMA CAR that comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 140, 141 or 166 and encoding a CACCR that comprises a polypeptide that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 99, 100, 180, 181, 182, 184, 185 or 186.

### Claim 40 (depends on 39)

A vector that comprises the isolated polynucleotide of claim 39.

### Claim 41 (depends on 40)

The vector of claim 40, wherein the BCMA CAR comprises the amino acid sequence of SEQ ID NO: 140, 141 or 166 and/or the CACCR comprises the amino acid sequence of SEQ ID NO: 99, 100, 180, 181, 182, 184, 185 or 186.

### Claim 42 (depends on 40)

The vector of claim 40, wherein the vector further comprises a promoter.

### Claim 43 (depends on 42)

The vector of claim 42, wherein the promoter comprises an EF-1alpha promoter.

### Claim 44 (depends on 40)

The vector of claim 40, wherein the vector is a lentiviral vector.

### Claim 45 (depends on 40)

The vector of claim 40 further comprising a mutant WPRE.

### Claim 46 (depends on 39)

An engineered immune cell that comprises the polynucleotide of claim 39.

### Claim 47 (depends on 1)

A method of making an engineered immune cell of claim 1 comprising introducing into a cell:
at least one polynucleotide that encodes a BCMA CAR and at least one polynucleotide that encodes a CACCR,
wherein the engineered immune cell expresses a BCMA CAR and a CACCR

### Claim 48 (depends on 47)

The method of claim 47, wherein the immune cell is a T cell, dendritic cell, killer dendritic cell, mast cell, NK-cell, macrophage, monocyte, B-cell or an immune cell derived from a stem cell.

### Claim 49 (depends on 47)

The method of claim 47, wherein the cell is autologous.

### Claim 50 (depends on 47)

The method of claim 47, wherein the cell is allogeneic.

### Claim 51 (depends on 47)

The method of claim 47, wherein the polynucleotide further encodes at least one selectable marker.

### Claim 52 (depends on 47)

The method of claim 47, wherein the polynucleotide is introduced into the cell by electroporation, transfection and/or viral transduction.
